Selank and Semax: Russian Neuropeptide Research Compounds

Origins: Russian Neuropeptide Research

Selank and Semax are both synthetic neuropeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (RAS) in Moscow. Their development was led primarily by Dr. Nikolai Myasoedov and colleagues over several decades of systematic research into small peptide fragments with central nervous system activity. Both compounds emerged from a research philosophy centred on the idea that fragments of endogenous neuropeptides could be engineered to retain biological activity while gaining the metabolic stability needed for practical research use.

Despite sharing this origin and institutional context, Selank and Semax are chemically distinct, act through different mechanisms, and have different primary research profiles. They are not interchangeable; understanding their mechanistic differences is essential for research design decisions.

Selank: The Tuftsin-Derived Anxiolytic Neuropeptide

Selank (also referred to by its development code TP-7) is a heptapeptide derived from tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of IgG in the spleen. Tuftsin itself has immunomodulatory properties and was originally studied in the context of immune cell activation. Selank is created by adding the tripeptide Pro-Gly-Pro to the C-terminus of tuftsin (giving the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro), which dramatically increases its metabolic stability without abolishing its biological activity.

Metabolic Stability

The addition of the Pro-Gly-Pro sequence protects Selank against rapid enzymatic degradation that would otherwise make it impractical as a research compound. Native tuftsin has a very short half-life in plasma (minutes); Selank's stability is substantially enhanced, making it more suitable for in vivo research applications.

Mechanisms: BDNF, Serotonin, and Anxiolytic Pathways

Selank's primary research focus is its anxiolytic profile — effects that reduce anxiety-like behaviour in animal models. The mechanistic basis is distinct from classical benzodiazepine anxiolytics (which work through GABA-A receptor potentiation). Published Selank research has identified several active mechanisms:

• BDNF modulation: Selank upregulates Brain-Derived Neurotrophic Factor (BDNF) expression in the hippocampus and frontal cortex. BDNF plays a critical role in synaptic plasticity, neuronal survival, and learning and memory. Elevated hippocampal BDNF is associated with reduced anxiety-like behaviour in animal models and is a target of interest in depression and anxiety neuroscience.
• Serotonin system modulation: Research has documented Selank's effects on serotonin metabolism, specifically altered serotonin turnover rates in brain regions involved in emotional processing. This monoamine pathway involvement contributes to the anxiolytic profile without the sedative and dependency risks associated with GABA-ergic drugs.
• Enkephalin degradation inhibition: Selank has been shown to inhibit enzymes responsible for degrading enkephalins — endogenous opioid peptides — potentially contributing to its mood-modulating effects through the endogenous opioid system.
• Immunomodulatory effects: Reflecting its tuftsin origins, Selank modulates immune parameters including T-helper cell balance and interleukin-6 expression. This immune-CNS crosstalk axis is an active area of neuropeptide research, given growing understanding of inflammatory pathways in neuropsychiatric conditions.

Cognitive Research Applications

Beyond anxiety, Selank research has examined cognitive effects in animal models. Studies have reported improvements in memory consolidation, attention, and associative learning metrics. These cognitive effects may be mechanistically linked to BDNF upregulation, as BDNF is a critical mediator of synaptic strengthening processes (long-term potentiation) underlying memory formation.

Semax: The ACTH-Derived Nootropic and Neuroprotectant

Semax is derived from the ACTH (Adrenocorticotropic Hormone) 4-10 fragment, a seven-amino acid sequence (Met-Glu-His-Phe-Arg-Trp-Gly) that had been identified as the cognitively active fragment of ACTH — the section of the molecule responsible for ACTH's nootropic effects without the adrenocortical stimulation of the full hormone. Semax is created by attaching a Pro-Gly-Pro C-terminal extension (the same stabilising tripeptide used in Selank) to this ACTH 4-10 fragment, extending its metabolic stability while preserving its CNS activity.

Mechanisms: Neurotrophin Upregulation and Neuroprotection

Semax's primary mechanistic signature in the literature is robust upregulation of neurotrophins — proteins that support neuronal survival, differentiation, and function. Key documented mechanisms include:

• BDNF upregulation: Semax is one of the most potent peptide upregulators of BDNF expression identified in published research, with effects documented in multiple brain regions including hippocampus, frontal cortex, and basal ganglia. The magnitude of BDNF upregulation reported for Semax consistently exceeds that documented for Selank, suggesting a stronger neurotrophin-stimulating profile.
• NGF (Nerve Growth Factor) upregulation: Research has documented Semax-induced upregulation of NGF in the brain, particularly in regions relevant to cholinergic neurotransmission. Cholinergic systems are central to learning, memory, and attention research, making NGF upregulation a notable finding for cognitive research models.
• TrkB receptor modulation: BDNF exerts most of its effects through the TrkB (Tropomyosin receptor kinase B) receptor. Research has examined whether Semax's BDNF-upregulating effects translate into enhanced TrkB signaling, with downstream effects on ERK, Akt, and PLCγ pathways involved in cell survival and synaptic plasticity.
• Neuroprotection in ischemia models: Some of the most striking published Semax research involves brain ischemia (stroke) models. Studies have demonstrated reduced infarct volume, improved neurological outcomes, and reduced inflammatory markers in rodent ischemia models. The proposed mechanisms include upregulation of anti-apoptotic signaling, reduction in excitotoxic glutamate effects, and mitigation of oxidative stress through reduced lipid peroxidation.
• Dopaminergic system effects: Semax has been shown to influence dopamine metabolism in mesolimbic and mesocortical pathways — brain circuits central to motivation, executive function, and reward processing. These effects contribute to the nootropic and motivational dimensions of Semax's research profile.

Comparing Selank and Semax

Despite their shared structural motif (the Pro-Gly-Pro C-terminal addition and their Russian research origins), Selank and Semax have meaningfully different research profiles:

• Parent molecule: Selank — tuftsin (immunomodulatory tetrapeptide); Semax — ACTH 4-10 fragment (melanocortin peptide)
• Primary research angle: Selank — anxiolytic, mood, serotonergic; Semax — cognitive enhancement, neuroprotection, BDNF/NGF
• BDNF upregulation: Both upregulate BDNF, but Semax demonstrates stronger and more consistent BDNF effects in published literature
• Immune effects: Selank — significant T-helper cell and interleukin modulation; Semax — immune effects less prominent
• Neuroprotection: Semax — extensive published data in ischemia models; Selank — neuroprotective effects exist but are less central to the research literature
• Combination rationale: The complementary mechanisms (anxiety and mood via Selank; cognition and neuroprotection via Semax) are the basis for combination research models studying both compounds together

Administration Routes in Research Models

Both Selank and Semax are commonly administered intranasally in research models, given that intranasal delivery provides a direct route to the olfactory bulb and CNS while bypassing systemic circulation and first-pass metabolism. Subcutaneous and intraperitoneal injection are used in rodent studies. The intranasal research administration route is of particular interest because it represents a potential practical delivery method that avoids injection.

Storage and Quality

Both compounds are supplied as lyophilised powders. Store at −20°C for long-term stability. Reconstituted solutions in bacteriostatic water are stable at 2–8°C for up to 28 days. COAs should confirm HPLC purity ≥98%, mass spectrometry identity (Selank MW ~751 Da, Semax MW ~887 Da), and endotoxin levels <5 EU/mg.

Frequently Asked Questions

What is Selank derived from?

Selank is a synthetic analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced in the spleen through enzymatic cleavage of immunoglobulin G. The Selank sequence adds Pro-Gly-Pro to the C-terminus of tuftsin to improve metabolic stability, giving the heptapeptide sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.

What is Semax derived from?

Semax is derived from the ACTH (4-10) fragment — the amino acid sequence from position 4 to position 10 of adrenocorticotropic hormone (Met-Glu-His-Phe-Arg-Trp-Gly). This fragment retains the nootropic activity of ACTH without the adrenocortical-stimulating effects of the full hormone. The Pro-Gly-Pro C-terminal extension added to create Semax improves metabolic stability.

Can Selank and Semax be researched together?

Yes. They are often studied in combination precisely because their mechanisms are complementary. Selank's anxiolytic and serotonergic activity addresses emotional state and anxiety-related behaviour, while Semax's BDNF/NGF upregulation and dopaminergic effects address cognitive performance and neuroprotection. Combination models allow researchers to explore whether these mechanistically distinct pathways produce additive or synergistic effects on cognitive and emotional research endpoints.

Is Semax the same as ACTH?

No. ACTH (Adrenocorticotropic Hormone) is a 39-amino acid peptide that stimulates the adrenal cortex to produce cortisol. Semax is derived from only a 7-amino acid fragment of ACTH (positions 4–10) with a Pro-Gly-Pro extension. This fragment lacks the cortisol-stimulating activity of the full hormone but retains and amplifies the cognitive/nootropic effects that were identified in the ACTH literature. Semax does not significantly stimulate cortisol production.

What does BDNF do and why is its upregulation significant?

BDNF (Brain-Derived Neurotrophic Factor) is a protein that supports the survival, growth, and differentiation of neurons, and plays a central role in synaptic plasticity — the strengthening and formation of new connections between neurons that underlies learning and memory. Low BDNF is associated with cognitive decline, depression, and neurodegenerative disease risk. Compounds that upregulate BDNF are of significant interest in neuroscience research as potential tools for studying cognitive enhancement, neuroprotection, and neuroplasticity mechanisms.

How does Selank differ from benzodiazepines in its anxiolytic mechanism?

Benzodiazepines produce anxiolytic effects by potentiating GABA-A receptor activity, enhancing the inhibitory effect of GABA throughout the brain — producing rapid, broad anxiolysis but also sedation, cognitive impairment, and dependency risk. Selank's anxiolytic mechanism operates primarily through the serotonergic system and BDNF pathway, without direct GABA-A receptor potentiation. This mechanistic difference is why Selank research is of interest for studying anxiolysis that doesn't carry benzodiazepine-associated liabilities.